Report ID: SQMIC35J2108
Report ID:
SQMIC35J2108 |
Region:
Country |
Published Date: February, 2024
Pages:
157
|
Tables:
36 |
Figures:
74
Amgen Inc. holds 40% of the US secondary hyperparathyroidism therapy (SHPT) market thanks to its substantial strategic decisions and robust pharmaceutical portfolio. SHPT is treated with Sensipar (Cinacalcet), a well-liked medication from Amgen. Generic manufacturers have only recently begun to enter the market as a result of numerous treatments' expiration of their patents. Organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz are among the market players. SHPT market expansion is also anticipated to be fueled by expanding generic manufacturer competition during the anticipated time frame.
US Secondary Hyperparathyroidism Treatment (SHPT) Market Top Player’s Company Profiles
Sanofi S.A.
F. Hoffmann-La Roche Ltd
AbbVie Inc.
Bayer AG
AstraZeneca Plc
Eli Lilly and Company
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Novartis AG
GlaxoSmithKline Plc
Merck & Co., Inc.
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company Ltd.
Boehringer Ingelheim International GmbH
Daiichi Sankyo Company, Limited
Astellas Pharma Inc.
Ipsen Biopharmaceuticals, Inc.
Mallinckrodt Pharmaceuticals
US Secondary Hyperparathyroidism Treatment (SHPT) Market
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIC35J2108